Abstract: The invention concerns a compound of formula (I), Formula (I), wherein R, R1 and R2 are independently selected form the group consisting of: —a hydrogen atom, —a halogen atom, —an alkyl group, linear, cyclic or branched, saturated or unsaturated, possibly substituted, comprising from 1 to 10 carbon atoms, —an acyl group comprising from 1 to 10 carbon atoms, —a carboxyl group, —an amido group comprising from 1 to 10 carbon atoms, and —an imino group, possibly substituted by an alkyl group, linear, cyclic or branched, saturated or unsaturated, and wherein R3, R4, R5 and R6 are independently selected form the group consisting of: —a hydrogen atom, —a halogen atom, —a hydroxyl group, —an alkyl group, linear, cyclic or branched, saturated or unsaturated, possibly substituted, comprising from 1 to 10 carbon atoms, —an alkoxy group comprising from 1 to 10 carbon atoms, —an acyl group comprising from 1 to 10 carbon atoms, —a carbonate group from 1 to 10 carbon atoms, —a carboxyl group, and —a cyano group.

Abstract: The invention relates to compounds of formula (I) as follows: (I) wherein X1 and X2, identical or different, are NR5 or a sulfur atom, Y is a group (C1-C10)alkanediyl, Ar1 and Ar2, identical or different, are an aryl group optionally substituted by one or several groups selected from a halogen atom, a (C1-C6) alkyl, —OR1, —NR1R2 and —COOR3? with R1 and R2, independently of each other, are a hydrogen atom, a (C-1-C6) alkyl group or a —COR3 group, R3 and R4? independently of each other, are a hydrogen atom or a (C1-C6) alkyl group, and R5 is a hydrogen atom or a (C1-C6)alkyl group, or a pharmaceutically acceptable salt and/or solvate thereof, in particular for use in cancer treatment.

Abstract: A compound derived from an aliphatic diamine including at least one pyridine or pyrimidine unit, for use as an anticancer agent, to a therapeutic composition including this compound, to a product including such a compound and another active agent, as well as to such a compound.

Abstract: The invention concerns a compound of formula (I), Formula (I), R, R1 and R2 are independently selected form the group consisting of: —a hydrogen atom, —a halogen atom, —an alkyl group, linear, cyclic or branched, saturated or unsaturated, possibly substituted, comprising from 1 to 10 carbon atoms, —an acyl group comprising from 1 to 10 carbon atoms, —a carboxyl group, —an amido group comprising from 1 to 10 carbon atoms, and —an imino group, possibly substituted by an alkyl group, linear, cyclic or branched, saturated or unsaturated, and wherein R3, R4, R5 and R6 are independently selected form the group consisting of: —a hydrogen atom, —a halogen atom, —a hydroxyl group, —an alkyl group, linear, cyclic or branched, saturated or unsaturated, possibly substituted, comprising from 1 to 10 carbon atoms, —an alkoxy group comprising from 1 to 10 carbon atoms, —an acyl group comprising from 1 to 10 carbon atoms, —a carbonate group from 1 to 10 carbon atoms, —a carboxyl group, and —a cyano group.

Abstract: The invention relates to compounds of formula (I) as follows: (I) wherein X1 and X2, identical or different, are NR5 or a sulfur atom, Y is a group (C1-C10)alkanediyl, Ar1 and Ar2, identical or different, are an aryl group optionally substituted by one or several groups selected from a halogen atom, a (C1-C6) alkyl, —OR1, —NR1R2 and —COOR3? with R1 and R2, independently of each other, are a hydrogen atom, a (C-1-C6) alkyl group or a —COR3 group, R3 and R4? independently of each other, are a hydrogen atom or a (C1-C6) alkyl group, and R5 is a hydrogen atom or a (C1-C6)alkyl group, or a pharmaceutically acceptable salt and/or solvate thereof, in particular for use in cancer treatment.